# CG Oncology, Inc.: financial statements, quarterly

CGON · Nasdaq · CIK 1991792 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cgon.md) · [Financials](/companies/cgon/financials.md) · [Filings](/companies/cgon/filings.md) · [Insiders](/companies/cgon/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cgon/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-124642.md) | [0.0 d](/filings/0001193125-26-079498.md) | [0.5](/filings/0000950170-25-069831.md) | [0.1](/filings/0000950170-25-105855.md) | [0.0](/filings/0001193125-25-283000.md) | [0.5 d](/filings/0001193125-26-079498.md) | [0.1](/filings/0001193125-26-214669.md) | [0.0](/filings/0001193125-26-336918.md) | [1.7](/filings/0001193125-25-283000.md) | [2.3 d](/filings/0001193125-26-079498.md) | [1.1](/filings/0001193125-26-214669.md) | [1.2](/filings/0001193125-26-336918.md) |
| Research and development | $m | [11.7](/filings/0000950170-24-124642.md) | [16.3 d](/filings/0001193125-26-079498.md) | [17.2](/filings/0000950170-25-069831.md) | [18.5](/filings/0000950170-25-105855.md) | [19.6](/filings/0001193125-25-283000.md) | [26.8 d](/filings/0001193125-26-079498.md) | [27.5](/filings/0001193125-26-214669.md) | [31.3](/filings/0001193125-26-336918.md) | [27.9](/filings/0001193125-25-283000.md) | [30.0 d](/filings/0001193125-26-079498.md) | [43.7](/filings/0001193125-26-214669.md) | [54.7](/filings/0001193125-26-336918.md) |
| Operating income | $m | [(14.0)](/filings/0000950170-24-124642.md) | [(19.4) d](/filings/0001193125-26-079498.md) | [(22.5)](/filings/0000950170-25-069831.md) | [(25.9)](/filings/0000950170-25-105855.md) | [(28.3)](/filings/0001193125-25-283000.md) | [(38.0) d](/filings/0001193125-26-079498.md) | [(42.2)](/filings/0001193125-26-214669.md) | [(48.7)](/filings/0001193125-26-336918.md) | [(51.1)](/filings/0001193125-25-283000.md) | [(48.7) d](/filings/0001193125-26-079498.md) | [(66.4)](/filings/0001193125-26-214669.md) | [(86.4)](/filings/0001193125-26-336918.md) |
| Net income | $m | [(11.8)](/filings/0000950170-24-124642.md) | [(16.6) d](/filings/0001193125-26-079498.md) | [(16.9)](/filings/0001193125-25-283000.md) | [(18.9)](/filings/0001193125-25-283000.md) | [(20.4)](/filings/0001193125-25-283000.md) | [(31.8) d](/filings/0001193125-26-079498.md) | [(34.5)](/filings/0001193125-26-336918.md) | [(41.4)](/filings/0001193125-26-336918.md) | [(43.8)](/filings/0001193125-25-283000.md) | [(41.3) d](/filings/0001193125-26-079498.md) | [(60.2)](/filings/0001193125-26-336918.md) | [(79.1)](/filings/0001193125-26-336918.md) |
| Diluted EPS | $ per share | [(4.00)](/filings/0000950170-24-124642.md) | not reported | [(0.36)](/filings/0000950170-25-069831.md) | [(0.28)](/filings/0000950170-25-105855.md) | [(0.30)](/filings/0001193125-25-283000.md) | not reported | [(0.45)](/filings/0001193125-26-214669.md) | [(0.54)](/filings/0001193125-26-336918.md) | [(0.57)](/filings/0001193125-25-283000.md) | not reported | [(0.71)](/filings/0001193125-26-214669.md) | [(0.90)](/filings/0001193125-26-336918.md) |
| Basic EPS | $ per share | [(4.00)](/filings/0000950170-24-124642.md) | not reported | [(0.36)](/filings/0000950170-25-069831.md) | [(0.28)](/filings/0000950170-25-105855.md) | [(0.30)](/filings/0001193125-25-283000.md) | not reported | [(0.45)](/filings/0001193125-26-214669.md) | [(0.54)](/filings/0001193125-26-336918.md) | [(0.57)](/filings/0001193125-25-283000.md) | not reported | [(0.71)](/filings/0001193125-26-214669.md) | [(0.90)](/filings/0001193125-26-336918.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [8.3](/filings/0000950170-25-046351.md) | [77.5](/filings/0000950170-24-056196.md) | [25.2](/filings/0000950170-24-093238.md) | [43.4](/filings/0000950170-24-124642.md) | [257](/filings/0001193125-26-079498.md) | [41.5](/filings/0000950170-25-069831.md) | [14.6](/filings/0000950170-25-105855.md) | [45.1](/filings/0001193125-25-283000.md) | [32.5](/filings/0001193125-26-336918.md) | [33.7](/filings/0001193125-26-214669.md) | [19.6](/filings/0001193125-26-336918.md) |
| Current assets | $m | not reported | [194](/filings/0000950170-25-046351.md) | [579](/filings/0000950170-24-056196.md) | [564](/filings/0000950170-24-093238.md) | [552](/filings/0000950170-24-124642.md) | [754](/filings/0001193125-26-079498.md) | [701](/filings/0000950170-25-069831.md) | [673](/filings/0000950170-25-105855.md) | [696](/filings/0001193125-25-283000.md) | [759](/filings/0001193125-26-336918.md) | [1,102](/filings/0001193125-26-214669.md) | [1,050](/filings/0001193125-26-336918.md) |
| Total assets | $m | not reported | [199](/filings/0000950170-25-046351.md) | [579](/filings/0000950170-24-056196.md) | [564](/filings/0000950170-24-093238.md) | [552](/filings/0000950170-24-124642.md) | [755](/filings/0001193125-26-079498.md) | [728](/filings/0000950170-25-069831.md) | [701](/filings/0000950170-25-105855.md) | [730](/filings/0001193125-25-283000.md) | [792](/filings/0001193125-26-336918.md) | [1,135](/filings/0001193125-26-214669.md) | [1,086](/filings/0001193125-26-336918.md) |
| Current liabilities | $m | not reported | [14.3](/filings/0000950170-25-046351.md) | [10.0](/filings/0000950170-24-056196.md) | [11.9](/filings/0000950170-24-093238.md) | [15.6](/filings/0000950170-24-124642.md) | [21.4](/filings/0001193125-26-079498.md) | [22.6](/filings/0000950170-25-069831.md) | [30.4](/filings/0000950170-25-105855.md) | [30.5](/filings/0001193125-25-283000.md) | [30.8](/filings/0001193125-26-336918.md) | [35.2](/filings/0001193125-26-214669.md) | [47.2](/filings/0001193125-26-336918.md) |
| Total liabilities | $m | not reported | [14.5](/filings/0000950170-25-046351.md) | [10.2](/filings/0000950170-24-056196.md) | [12.0](/filings/0000950170-24-093238.md) | [15.7](/filings/0000950170-24-124642.md) | [21.4](/filings/0001193125-26-079498.md) | [23.4](/filings/0000950170-25-069831.md) | [31.1](/filings/0000950170-25-105855.md) | [42.3](/filings/0001193125-25-283000.md) | [39.0](/filings/0001193125-26-336918.md) | [43.5](/filings/0001193125-26-214669.md) | [56.5](/filings/0001193125-26-336918.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-079498.md) | not reported | not reported | [3.0](/filings/0001193125-25-283000.md) | [3.0](/filings/0001193125-26-336918.md) | [3.0](/filings/0001193125-26-214669.md) | [3.0](/filings/0001193125-26-336918.md) |
| Shareholders' equity | $m | [(108)](/filings/0000950170-24-124642.md) | [(123)](/filings/0001193125-26-079498.md) | [569](/filings/0001193125-25-283000.md) | [552](/filings/0001193125-25-283000.md) | [537](/filings/0001193125-25-283000.md) | [733](/filings/0001193125-26-336918.md) | [705](/filings/0001193125-26-336918.md) | [670](/filings/0001193125-26-336918.md) | [688](/filings/0001193125-25-283000.md) | [753](/filings/0001193125-26-336918.md) | [1,092](/filings/0001193125-26-336918.md) | [1,029](/filings/0001193125-26-336918.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.3) d](/filings/0000950170-24-124642.md) | [(14.6) d](/filings/0001193125-26-079498.md) | [(26.0)](/filings/0000950170-25-069831.md) | [(16.1) d](/filings/0000950170-25-105855.md) | [(15.9) d](/filings/0001193125-25-283000.md) | [(20.7) d](/filings/0001193125-26-079498.md) | [(29.3)](/filings/0001193125-26-214669.md) | [(28.0) d](/filings/0001193125-26-336918.md) | [(38.9) d](/filings/0001193125-25-283000.md) | [(36.2) d](/filings/0001193125-26-079498.md) | [(56.9)](/filings/0001193125-26-214669.md) | [(46.4) d](/filings/0001193125-26-336918.md) |
| Capital expenditure | $m | not reported | not reported | [0.0](/filings/0000950170-25-069831.md) | [0.0 d](/filings/0000950170-25-105855.md) | [(0.0) d](/filings/0001193125-25-283000.md) | [0.2 d](/filings/0001193125-26-079498.md) | [0.0](/filings/0001193125-26-214669.md) | [0.0 d](/filings/0001193125-26-336918.md) | [0.1 d](/filings/0001193125-25-283000.md) | [0.0 d](/filings/0001193125-26-079498.md) | [0.3](/filings/0001193125-26-214669.md) | [0.5 d](/filings/0001193125-26-336918.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.9](/filings/0000950170-24-056196.md) | [3.9](/filings/0000950170-24-093238.md) | [4.4](/filings/0000950170-24-124642.md) | [47.1](/filings/0000950170-25-069831.md) | [66.6](/filings/0000950170-25-105855.md) | [67.1](/filings/0001193125-25-283000.md) | [76.2](/filings/0001193125-26-214669.md) | [76.2](/filings/0001193125-26-336918.md) | [76.7](/filings/0001193125-25-283000.md) | [84.5](/filings/0001193125-26-214669.md) | [88.2](/filings/0001193125-26-336918.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 88,640,375 at 2026-08-05, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336918.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.